The Department of Health and Human Services today proposed implementing on Jan. 1 its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers.
Sep 18, 2018
Leaders from the AHA and individual 340B hospitals today came together to announce new principles for ensuring good stewardship of the 340B program. The new AHA-led initiative seeks to strengthen the 340B program by increasing transparency while helping 340B hospitals better publicly communicate…
Sep 22, 2020
AHA 340B Advocacy Alliance Member Only Webinar September 16, 2020
Sep 10, 2020
Improving the health of their communities is at the heart of every hospital’s mission. As one example, in a new analysis released, the American Hospital Association (AHA) found that 340B tax-exempt hospitals provided more than $64.3 billion in total benefits to their communities in 2017 alone, the…
Sep 10, 2020
Improving the health of their communities is at the heart of every hospital’s mission. Tax-exempt hospitals are required to publicly report on the ways in which they improve the health of the communities they serve yearly through the IRS Form 990 Schedule H, which is publicly available.
Sep 9, 2020
In response to recent actions taken by a number of drug companies to limit the distribution of certain 340B drugs to hospitals and health systems, Reps. Diana DeGette, D-Colo., and David McKinley, R-W.Va., along with Reps. Peter Welch, D-Vt., Greg Gianforte, R-Mont., Dusty Johnson, R-S.D., and…
Sep 8, 2020
The AHA again expressed concern to the Department of Health and Human Services about recent actions taken by several major drug manufacturers to limit the distribution of certain 340B drugs to hospitals.
Sep 8, 2020
AHA to HHS again expressing concern with recent actions taken by several major drug manufacturers to limit the distribution of certain 340B drugs to our hospital members.
Sep 2, 2020
Statement on the FY 2021 final IPPS rule from AHA Senior Vice President for Public Policy Analysis and Development Ashley Thompson.
Aug 27, 2020
The AHA and other national health care groups urged the Department of Health and Human Services to protect 340B hospitals and the vulnerable communities they serve “from actions taken by five of the nation’s largest pharmaceutical manufacturers that undermine access to critical drugs and other…